Tezepelumab治疗中国重度慢性鼻窦炎伴鼻息肉患者的WAYPOINT三期预设亚组分析
WAYPOINT三期试验的预设中国亚组分析纳入29例接受tezepelumab、34例接受安慰剂的重度慢性鼻窦炎伴鼻息肉患者,治疗52周。Tezepelumab在鼻息肉总分、鼻塞评分、嗅觉丧失、SNOT-22、Lund-Mackay评分及NPSD总分上均较安慰剂数值上更优,且无患者需鼻息肉手术或全身糖皮质激素。
要点
- 中国亚组中tezepelumab在鼻息肉大小和鼻塞方面数值上优于安慰剂
- tezepelumab改善嗅觉丧失、SNOT-22、Lund-Mackay和NPSD总分
- tezepelumab组无患者需鼻息肉手术或全身糖皮质激素
核心结论
- 与总体人群一致,tezepelumab缩小中国CRSwNP患者鼻息肉并改善嗅觉丧失等症状,安全性良好。
研究设计与样本
- WAYPOINT(NCT04851964)三期试验的预设中国亚组分析。
- 成人重度CRSwNP患者按1:1随机接受tezepelumab 210 mg或安慰剂治疗52周。
- 中国亚组共63例,tezepelumab组29例,安慰剂组34例。
主要发现
- 第52周鼻息肉总分较基线的最小二乘均值差(tezepelumab vs 安慰剂)为-2.03(95%CI -2.88至-1.19)。
- 双周平均鼻塞评分的最小二乘均值差为-0.72(95%CI -1.23至-0.21)。
- NPSD嗅觉丧失评分差为-0.44(95%CI -0.82至-0.06),SNOT-22总分差为-16.34(95%CI -29.80至-2.88)。
- Lund-Mackay评分差为-5.30(95%CI -7.23至-3.38),NPSD总分差为-3.76(95%CI -6.89至-0.63)。
- tezepelumab组无患者需鼻息肉手术或全身糖皮质激素。
关键数值与推荐
- 共同主要终点为第52周鼻息肉总分和双周平均鼻塞评分较基线的变化。
- 关键次要终点包括NPSD嗅觉丧失评分、SNOT-22总分、Lund-Mackay评分、NPSD总分及首次鼻息肉手术和/或全身糖皮质激素使用时间。
临床怎么用
- 中国重度CRSwNP患者中tezepelumab可考虑用于缩小鼻息肉和改善鼻塞、嗅觉等症状。
- 该亚组中tezepelumab治疗52周内无患者需手术或全身糖皮质激素。
- 疗效在基线嗜酸性粒细胞计数相对较低的中国患者中仍可观察到。
局限性
- 中国亚组样本量较小(tezepelumab组29例,安慰剂组34例)。
- 结果需进一步研究以评估对中国更广泛CRSwNP人群的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese patients with CRSwNP. METHODS: Adult patients with severe CRSwNP were randomized 1:1 to tezepelumab (210 mg) or placebo for 52 weeks. Co-primary endpoints were changes from baseline at Week 52 (W52) in total nasal-polyp score and bi-weekly mean nasal-congestion score. Key secondary endpoints included changes from baseline in Nasal Polyposis Symptom Diary (NPSD) loss-of-smell score, 22-item Sinonasal Outcome Test (SNOT-22) total score, Lund-Mackay score, NPSD total symptom score, and time to first nasal-polyp surgery decision and/or systemic glucocorticoid use. RESULTS: Twenty-nine patients received tezepelumab, and 34 received placebo. At W52, tezepelumab achieved numerically greater improvements in total nasal-polyp score (least-squares mean difference vs. placebo [95% CI]: -2.03 [-2.88, -1.19]) and bi-weekly mean nasal-congestion score (-0.72 [-1.23, -0.21]). Compared with placebo, tezepelumab also improved NPSD loss-of-smell score (-0.44 [-0.82, -0.06]), SNOT-22 total score (-16.34 [-29.80, -2.88]), Lund-Mackay score (-5.30 [-7.23, -3.38]), and NPSD total symptom score (-3.76 [-6.89, -0.63]). No tezepelumab-treated patients required nasal-polyp surgery or systemic glucocorticoids. CONCLUSION: Consistent with the overall population, tezepelumab reduced nasal-polyp size and improved loss-of-smell and other sinonasal symptoms in Chinese patients with CRSwNP, with a favorable safety profile. No surgery or systemic glucocorticoids were required. These benefits were observed despite relatively lower baseline eosinophil counts in these patients. Further investigation is warranted to assess the generalizability to the broader Chinese population with CRSwNP.
引用
- Hu L, Li H, Sun X, et al. Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial. Int Forum Allergy Rhinol. 2026. PMID: 42525496. doi:10.1002/alr.70208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。